EP 4340847 A4 20240717 - COMPOSITION OF MESALAZINE ENTERIC TABLET FORMULATION
Title (en)
COMPOSITION OF MESALAZINE ENTERIC TABLET FORMULATION
Title (de)
ZUSAMMENSETZUNG EINER MESALAZIN-ENTERUSTABLETTENFORMULIERUNG
Title (fr)
COMPOSITION DE FORMULATION DE COMPRIMÉ ENTÉRIQUE À BASE DE MÉSALAZINE
Publication
Application
Priority
TR 2021050472 W 20210521
Abstract (en)
[origin: WO2022245307A1] A formulation of a pharmaceutical enteric tablet composition comprising mesalazine, a process for the production of said formulation with a multilayer enteric coating that provides required in-vitro dissolution profiles showing the specific delivery of the active substance contained in the dosage form to the colon initially and during storage under stability conditions.
IPC 8 full level
A61K 31/606 (2006.01); A61J 3/00 (2006.01); A61K 9/16 (2006.01); A61K 9/28 (2006.01); A61P 1/04 (2006.01)
CPC (source: EP)
A61J 3/005 (2013.01); A61K 9/1652 (2013.01); A61K 9/2846 (2013.01); A61K 9/2886 (2013.01); A61K 31/606 (2013.01); A61P 1/04 (2018.01)
Citation (search report)
- [YD] US 2012282333 A1 20121108 - KAKUMANU VASU KUMAR [IN], et al
- [Y] CA 2187741 A1 19951102 - YAMANOUCHI PHARMA CO LTD [JP]
- [Y] ANONYMOUS: "Summary of Product Characteristics (SmPC) for Salofalk 500 mg gastro-resistant tablets", MEDICINES.ORG, 1 January 2018 (2018-01-01), pages 1 - 5, XP055534701, Retrieved from the Internet <URL:https://www.medicines.org.uk/emc/product/5785/smpc/print> [retrieved on 20181214]
- See also references of WO 2022245307A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022245307 A1 20221124; EP 4340847 A1 20240327; EP 4340847 A4 20240717
DOCDB simple family (application)
TR 2021050472 W 20210521; EP 21940969 A 20210521